Literature DB >> 8628288

Human chromosome 3 mediates growth arrest and suppression of apoptosis in microcell hybrids.

M D Speevak1, M Chevrette.   

Abstract

Chemotherapeutic treatment of tumor cells leads either to tumor cell death (usually by apoptosis) or to the formation of drug-resistant subpopulations. Known mechanisms of cancer cell drug resistance include gene amplification and increased expression of drug transporters. On the other hand, normal cells survive many forms of chemotherapy with minimal damage probably because of their capacity for growth arrest and stringent control of apoptosis. Microcell hybrids between B78 (murine melanoma) and HSF5 (normal human fibroblasts) were analyzed to identify a new human chromosomal region involved in the promotion of drug-induced growth arrest and suppression of apoptosis. In these hybrids, the presence of human chromosome 3 was strongly associated with suppression of apoptosis via G1 and G2 growth arrest during exposure to the antimetabolite N-phosphonoacetyl-L-aspartate (PALA), suggesting that a gene(s) on chromosome 3 serves an antiproliferative role in a drug-responsive growth arrest pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8628288      PMCID: PMC231209          DOI: 10.1128/MCB.16.5.2214

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  69 in total

1.  p53-mediated apoptosis in HeLa cells can be overcome by excess pRB.

Authors:  Y Haupt; S Rowan; M Oren
Journal:  Oncogene       Date:  1995-04-20       Impact factor: 9.867

2.  Identification of chromosomes implicated in suppression of apoptosis in somatic cell hybrids.

Authors:  M D Speevak; M Chevrette
Journal:  Biochem Cell Biol       Date:  1994 Nov-Dec       Impact factor: 3.626

Review 3.  Apoptosis in cancer therapy: crossing the threshold.

Authors:  D E Fisher
Journal:  Cell       Date:  1994-08-26       Impact factor: 41.582

4.  Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells.

Authors:  K J Russell; L W Wiens; G W Demers; D A Galloway; S E Plon; M Groudine
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

5.  The drug resistance-related protein LRP is the human major vault protein.

Authors:  G L Scheffer; P L Wijngaard; M J Flens; M A Izquierdo; M L Slovak; H M Pinedo; C J Meijer; H C Clevers; R J Scheper
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

6.  Specific growth inhibitory sequences in genomic DNA from quiescent human embryo fibroblasts.

Authors:  R Padmanabhan; T H Howard; B H Howard
Journal:  Mol Cell Biol       Date:  1987-05       Impact factor: 4.272

7.  Complexity of the early genetic response to growth factors in mouse fibroblasts.

Authors:  J M Almendral; D Sommer; H Macdonald-Bravo; J Burckhardt; J Perera; R Bravo
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

8.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.

Authors:  I B Roninson; J E Chin; K G Choi; P Gros; D E Housman; A Fojo; D W Shen; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

9.  Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells.

Authors:  M Oren; W Maltzman; A J Levine
Journal:  Mol Cell Biol       Date:  1981-02       Impact factor: 4.272

10.  Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells.

Authors:  L F Lau; D Nathans
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598

View more
  1 in total

1.  Isolation and characterization of mouse-human microcell hybrid cell clones permissive for infectious HIV particle release.

Authors:  Ayse K Coskun; Marc van Maanen; David Janka; David Stockton; Pawel Stankiewicz; Pawel Stankiewicsz; Svetlana Yatsenko; Richard E Sutton
Journal:  Virology       Date:  2007-01-31       Impact factor: 3.616

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.